Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF/MEK inhibition

Kavitha Gowrishankar, Stephanie Snoyman, Gulietta M. Pupo, Therese M. Becker, Richard F. Kefford, Helen Rizos

Research output: Contribution to journalArticlepeer-review

62 Citations (Scopus)


Aberrant activation of the BRAF kinase occurs in ∼60% of melanomas, and although BRAF inhibitors have shown significant early clinical success, acquired resistance occurs in most patients. Resistance to chronic BRAF inhibition often involves reactivation of mitogen-activated protein kinase (MAPK) signaling, and the combined targeting of BRAF and its downstream target MAPK/ERK kinase (MEK) may delay or overcome resistance. To investigate the efficacy of combination BRAF and MEK inhibition, we generated melanoma cell clones resistant to the BRAF inhibitor GSK2118436. These BRAF inhibitor-resistant sublines acquired resistance through several distinct mechanisms, including the acquisition of activating N-RAS mutations and increased accumulation of COT1. These alterations uniformly promoted MAPK reactivation and most conferred resistance to MEK inhibition and to the concurrent inhibition of BRAF and MEK. These data indicate that melanoma tumors are likely to develop heterogeneous mechanisms of resistance, many of which will confer resistance to multiple MAPK inhibitory therapies.

Original languageEnglish
Pages (from-to)1850-1859
Number of pages10
JournalJournal of Investigative Dermatology
Issue number7
Publication statusPublished - Jul 2012
Externally publishedYes

Bibliographical note

A correction for this article exists in the Journal of Investigative Dermatology, vol. 133, issue 10, p. 2493. DOI: 10.1038/jid.2013.125


Dive into the research topics of 'Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF/MEK inhibition'. Together they form a unique fingerprint.

Cite this